Core Viewpoint - Myp Medtech has experienced a decline in stock price, dropping 5.01% on September 4, with a total market value of 4.757 billion yuan and a cumulative drop of 6.43% over three days [1] Company Overview - Myp Medtech, established on September 2, 2008, and listed on July 26, 2021, is located in Huangpu District, Guangzhou, Guangdong Province. The company specializes in developing high-performance implantable medical devices using advanced manufacturing technology and synthetic materials [1] - The main revenue components are: artificial dura (spinal) membrane patches at 45.42%, craniofacial repair and fixation systems at 28.17%, absorbable regenerated oxidized cellulose and dura mater medical glue at 24.39%, and other supplementary products at 2.03% [1] Fund Holdings - Dongxing Fund has one fund heavily invested in Myp Medtech, specifically the Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A (020830), which held 3,408 shares in the second quarter, accounting for 3.5% of the fund's net value, ranking as the seventh largest holding [2] - The fund has incurred a floating loss of approximately 12,800 yuan today, with a total floating loss of 17,600 yuan during the three-day decline [2] Fund Manager Information - The fund manager of Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A is Li Bingwei, who has been in the position for 9 years and 86 days. The total asset size of the fund is 352 million yuan, with the best return during his tenure being 60.76% and the worst being -11.19% [3]
迈普医学股价跌5.01%，东兴基金旗下1只基金重仓，持有3408股浮亏损失1.28万元